Kornimate/medical-research-clean huggingface dataset:
cryoablation with vestibular expansion for the treatment of paroxysmal/short-course persistent atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the purpose of this study was to verify the safety and efficacy of routine and extended vestibular ablation in the treatment of paroxysmal/short-course persistent atrial fibrillation.

the purpose of this study was to verify the safety and efficacy of routine and extended vestibular ablation using the medtronic arctic front advancetm catheter in the treatment of paroxysmal/short-course persistent atrial fibrillation

Eligibility criteria:
inclusion criteria: 1. 18 years old ≤ age ≤ 85 years old; 2. patients with paroxysmal/short-term persistent atrial fibrillation; 3. be able to understand the purpose of the research, voluntarily participate in the research and sign the informed consent. exclusion criteria: 1. echocardiography shows that the left atrium diameter is greater than or equal to 45mm; 2. preoperative ct or esophageal echocardiography suggests that there is a thrombus in the left atrium/left atrial appendage; 3. those who have undergone left atrial ablation or left atrial surgery; 4. those who have received simple left atrial appendage occlusion; 5. new york heart function class (nyha) class iii or iv congestive heart failure or lvef (%) less than 40%; 6. those who have undergone valve repair; 7. preoperative electrocardiogram or holter confirmed the presence of typical atrial flutter or other supraventricular tachycardia (holding the duration is greater than 30 s); 8. secondary atrial fibrillation, including uncontrolled hyperthyroidism, acute alcoholism, cardiac surgery postoperative atrial fibrillation, etc.; 9. history of acute coronary events or percutaneous coronary stent intervention within 6 months before enrollment; 10. those with a history of cardioverter-defibrillator (icd) implantation or a history of cardiac resynchronization therapy (crt); 11. history of stroke or transient ischemic attack within 6 months before enrollment; 12. those with obvious bleeding tendency who cannot receive postoperative systemic anticoagulation; 13. severe structural heart disease, including moderate to severe mitral insufficiency or stenosis, previous myocardial infarction, hypertrophic cardiomyopathy, etc.; 14. combined with other serious diseases, the life expectancy is less than 12 months; 15. women who are pregnant, breastfeeding and planning to become pregnant; 16. have participated in or are participating in clinical investigators of other drugs or devices within 3 months before enrollment; 17. other conditions assessed by the investigator to be unsuitable for inclusion in this study, such as persons with mental disorders or mental disorders.
basiliximab in moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.


Eligibility criteria:
inclusion criteria: in addition to others, * men or women age 18-75 * diagnosis of ulcerative colitis confirmed through screening endoscopy. * extent of disease must involve at least the left colon * moderate to severe disease (mayo score 6-12). systemic features of tachycardia, fever, and/or significant anemia should not be present. * inadequate response despite treatment with prednisone 40 - 50 mg/day (or other oral steroid at equivalent dose) orally for a minimum of 14 days immediately preceding study entry exclusion criteria: in addition to other protocol-defined conditions, * pregnancy * stool study that shows presence of ova and parasites, significant bacterial pathogens, or c. difficile toxin * colitis that is indeterminate, suggestive of crohn's disease, or isolated to the rectum, based on endoscopic and/or biopsy findings * severely ill patients as evidenced by protocol-defined systemic criteria * chest radiograph abnormalities consistent with an infectious process * history of colonic dysplasia * hiv infection * known viral hepatitis b or c infection * history of or exposure to tuberculosis within 6 months before study entry

Keywords: ulcerative colitis basiliximab
the prevalence and impacts of nudix hydrolase 15 (nudt15) gene variants in taiwanese inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases; Neutropenia; Nudt15 Deficiency

Summary: the study will include participants who were diagnosed with inflammatory disease and followed up at national taiwan university children's hospital. the investigators will check the nudt15 gene test, if the participant agrees to do an additional blood test. the result of the gene test will be analyzed and compared with other clinical data.

in inflammatory bowel disease (ibd), thiopurines play an important role in maintenance of steroid-free remission but possess risk of life-threatening neutropenia, which is associated with gene variants of nudt15 in asians. in order to better incorporate thiopurines in clinical practice, the investigators aim to summarize the prevalence and impacts of nudt15 variation in ibd in taiwan. the study will include participants who were diagnosed with inflammatory disease and followed up at national taiwan university children's hospital. the investigators will check the nudt15 gene test, if the participant agrees to do an additional blood test. the result of the gene test will be analyzed and compared with other clinical data.

Eligibility criteria:
inclusion criteria: * participants who are diagnosed with inflammatory bowel disease. exclusion criteria: * participants who refused to have blood test for nudt15 gene evaluation.
evaluating an alternative clinical genetics cancer care delivery model: a pilot study of patient outcomes

Conditions: Ovarian Cancer; Prostate Cancer; Pancreas Cancer

Summary: this study will evaluate patients' experiences with having gynecologic or prostate medical oncologists and surgeons offer them genetic testing, and having genetic counselors return the test results to patients over the telephone. this is different from the usual approach to genetic testing, where gynecologic or prostate medical oncologists and surgeons refer their patients to a genetic counselor in order to have these tests done, and the genetic counselors return the test results to the patient in person or over the telephone. the investigators will only be evaluating this alternative way of providing genetic testing to ovarian or prostate cancer patients.


Eligibility criteria:
inclusion criteria: * msk patient age 18 years or older. * diagnosed with or presumed by physician to have prostate cancer, or pancreatic cancer and recommended to undergo, currently undergoing, or having undergone active surveillance. (patients with invasive epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer, or pancreas cancer are no longer eligible for inclusion as of amendment 9. patients with advanced prostate cancer who have not participated in active surveillance are no longer eligible for inclusion as of amendment 10) * deemed to be clinically appropriate for multiplex genetic testing by their physician. * agreed to receive clinical multiplex genetic testing from their physician. * english-fluent; the surveys were designed and validated in english and are not currently available in other languages. translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. therefore, participants must be able to communicate in english to complete the surveys. exclusion criteria: * patients who do not or will not receive their ongoing cancer care at msk. * major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation. * any patients who are unable to comply with the study procedures as determined by the study investigators or study staff. * for ovarian cancer patients only: patient insured by a payer that does not provide coverage for multiplex genetic testing as delivered in this protocol (e.g., cigna, united health care, or oxford, (because these payers require genetic counseling by a genetics professional prior to testing).

Keywords: genetic testing 16-919
individualized peep setting by eit in patients with ards

Conditions: the PEEP Setting of ARDS

Summary: the investigators conducted a pilot study to compare the effect of positive end expiratory pressure(peep) setting guide by lung electrical impedance tomography(eit) and ards-net peep-fio2 table on survival in subjects with mild/severe acute respiratory distress syndrome(ards).


Eligibility criteria:
inclusion: 1. acute respiratory distress syndrome with ratio of partial pressure of arterial oxygen over fraction of inspired oxygen (pao2:fio2)\ 5cmh2o 2. body mass index \< =40 3. written inform consent exclusion: 1. pregnant，intracranial hypertension 2. left ventricular dysfunction (ef\<25% ) 3. patients with end-stage conditions(death expected within 90 days)
neoadjuvant endocrinotherapy of breast cancer (mamma carcinoma) with exemestane

Conditions: Breast Cancer

Summary: the objective of the present clinical investigation is to determine whether hormonal therapy given preoperatively is able to reduce tumor size to an extent that facilitates breast-conserving procedures.

this open, prospective multicenter phase ii pilot trial investigates the efficacy of exemestane, 25 mg once daily over 4 months, in postmenopausal women with primary breast cancer, measured in terms of clinical response

Eligibility criteria:
inclusion criteria: * histologically verified breast cancer (punch biopsy), established her-2/neu status * postmenopausal patients (\> 1 year following outset of menopause and/or postmenopausal hormonal profile) * clinical staging: t2 (\> 3 cm), t3, t4a-c, n0-1 * hormone receptor positivity, i.e. estrogen and/or progesterone receptor \> 10 fmol/mg cytosolic protein or er-ica-positive and/or pgr-ica-positive. positivity of + (low-grade) in one hormone receptor is only eligible in the presence of positivity in the other hormone receptor. * no internal contraindication * life expectation \> 6 month * written informed consent exclusion criteria: * premenopausal patients and patients with no clearly indicated menopausal status * manifest second malignant tumor (except basalioma or in situ carcinoma of cervix uteri) * uncontrolled internal disease i.e. diabetes mellitus, cardiac disease (nyha iii/iv) * thromboembolic disease * inflammatory mamma carcinoma * existence of distant metastases * former or simultaneously therapy with antioestrogens, aromatase inhibitors, cytostatics or radiotherapy * corticosteroids before and during the study (except inhalant application) * lack of compliance

Keywords: pilot study exemestane endocrinotherapy mamma carcinoma neoadjuvant abcsg 17
preemptive ketorolac for shoulder tip pain during cesarean section

Conditions: Cesarean Section

Summary: our study is planned to investigate if pre-emptive ketorolac would decrease the incidence of intraoperative shoulder tip pain and improve discomfort during caesarean section.

cesarean section (cs) is the most frequent major abdominal surgery among women worldwide . shoulder pain, is a common but mostly neglected consequence of caesarean section and little is known about this entity. the pain is described as sharp, deep and referred, usually begins intraoperatively and continue for 2-3 days after surgery. although infant and maternal death rates have been decreased after cs, this procedure is not free of risks for mother and child. compared with normal vaginal delivery (nvd), some cs complications include: more haemorrhage; increased postoperative pain; atelectasia; nausea; vomiting; risks for wound infection or wound opening and shoulder pain. although spinal anaesthesia (sa) is a common technique for cs in the past decade, and there are many studies about cs complications, there are few studies about shoulder pain as one of cs complications. kikuchi et al. reported that women undergoing cesarean section under compined spinal epidural anaethesia experience shoulder-tip pain with great frequency. our study was planned and performed to investigate if pre-emptive ketorolac would decrease the incidence of intraoperative shoulder pain and improve discomfort during cs. sharp pain observed in these patients was experienced in the shoulder area or under the diaphragm. the pain was described as coming from deep within the shoulder, and in some, would seem to radiate from the right chest. the pain spread down the upper right arm and up the right neck in some, resulting in muscular tension and pain. the cause of this pain is postulated to sub-diaphragmatic air trapping, subdiaphragmatic clot or peritoneal irritation. this type of shoulder pain is reported commonly after laparoscopic surgery and it is reported that heat, massage and drinking hot water or hot tea with fresh lemon relieves this pain.

Eligibility criteria:
inclusion criteria: * nulligravida healthy women who delivered single term baby, with american society of anesthesiologists physical status 1 or 2 exclusion criteria: previous caesarean section; pre-eclampsia; gestational diabetes; trauma; fractures or chronic pain in shoulder joints, forearms, upper limbs; cardiovascular or biliary system disorders; women undergoing emergency caesarean; previous history of abdominal surgery; conditions preventing spinal block, including local infection; coagulopathies; haemodynamic instability
long-term efficacy of orthokeratology contact lens wear in controlling the progression of childhood myopia

Conditions: Myopia, Progressive; Children, Only

Summary: to assess the long-term efficacy of the menicon z night orthokeratology contact lens in controlling the progression of childhood myopia

this prospective, controlled, parallel, longitudinal study compared the axial length growth of white european myopic children wearing menicon z night orthokeratology contact lenses to a control group over a 7-year period.

Eligibility criteria:
inclusion criteria: * be 6 to 12 years of age, both ages inclusive * a low-to-moderate level of myopia (between -0.75 and -4.00 d) and of astigmatism (≤ 1.00 d) * neophyte contact lens wearer * be successfully fitted with spectacles or orthokeratology contact lenses * be able to achieve, through spherical refraction correction, a logmar visual acuity of 0.8 or better in each eye * be willing and able to follow the subject instructions and to meet the protocol-specified schedule of follow-up visits * white european ethnicity exclusion criteria: * systemic or ocular disease affecting ocular health * use of any systemic or topical medications that could affect ocular physiology or contact lens performance * any lid or anterior segment abnormalities for which contact lens wear could be contraindicated * cclru grade ≥ 2 for any given anterior segment ocular clinical signs * aphakic, amblyopic, and atopic individuals * refractive astigmatism ≥ ½ spherical refraction * previous contact lens wear
low grade inflammation in childhood obesity : an independent risk factor for endothelial dysfunction

Conditions: Obesity, Childhood; Obesity; Endothelial Dysfunction; Cardiovascular Risk Factor; Inflammation

Summary: eligible candidates will be recruited within the children with overweight and obesity having a metabolic risk evaluation before treatment in the period 2006 and 2010 at the pediatric clinic of the uz brussel in total 60 participants will be investigated. firstly, 30 participating patients with initially elevated hscrp will be selected at random ( following the date of their initial investigation) and afterwards matched for age, bmi z-score, and blood pressure with the same number of patients without initially elevated hcrp values data will be collected as follows: * questionnaires * clinical examination/ anthropometry * blood sample (hscrp) * peripheral arterial tonometry (endopat)

obesity and overweight have become an important health burden in children and adolescents, with 19% of all children between 5 and 18 years being either obese or overweight in belgium. obesity and especially visceral adiposity early in life may contribute to the development of cardiovascular disease at older age, as it shows tracking into adulthood and is be associated with cardiovascular risk factors such as dyslipidemia, insulin resistance, arterial hypertension and low grade inflammation, in a variable percentage. low grade inflammation, as assessed by hscrp, was found to be present in 20.6 % and 19.8 % of overweight children and adolescents. in adults, hscrp levels between 1 and 3 mg/l and above 3 mg/l are considered coronary disease risk factors. endothelial dysfunction, know to precede the formation of atherosclerotic plaque, can be assessed in a non-invasive manner in children by peripheral artery tonometry. only few studies have been performed in obese children with this bed-side technique, showing either normal of a disturbed function, reflected by a lower reactive hyperemia index. the association with low grade inflammation however was assessed in only one study. the investigators hypothesize that in adolescents and young adults with a history of childhood obesity a more disturbed endothelial function will be present in those with and /or current elevated hscrp value.

Eligibility criteria:
inclusion criteria: * age 12-21 years at the moment of evaluation * bmi \> 1.3 standard deviation score at the initial evaluation * hs-crp available at initial evaluation exclusion criteria: * acute of chronic infection at the time of the study visit * be or have been a smoker of tabacco
impact evaluation of personalized oral hygiene education on periodontal patients stage i/ii/iii

Conditions: Periodontal Disease Stage I/II/III

Summary: evaluation of personalized oral hygiene education on plaque accumulation and gingival inflammation in periodontal patients stage i/ii/iii. evaluation of personalized oral hygiene education on clinical attachment level in periodontal patients stage i/ii/iii. evaluation of personalized oral hygiene education on the psychological determinants described by the health action process approach (hapa) and the mediating role of these psychological determinants in oral hygiene habits and clinical parameters in periodontal patients stage i/ii/iii.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old * subject having signed an informed consent * subjects with periodontal disease stage i/ii/iii : * ≥ 15 teeth/implants * bleeding index at ≥ 25% * plaque index ≥ 20% * not requiring antibiotic prophylaxis prior to periodontal treatment. * not having received surgical periodontal treatment in the last 12 months. * smokers of ≤10 cigarettes/day exclusion criteria: * \<15 teeth/implants * physical or mental disability that does not allow for the performance of oral hygiene procedures. * chronic progressive pathology (diabetes...) / immunodeficiencies (hiv...)/ systemic infections. * ongoing drug treatment leading to a significant change in the periodontal condition (anti-epileptics, calcium antagonists, immunosuppressants, hormonal treatments, etc.). * ongoing drug treatment that can influence the periodontal condition (anti-inflammatory drugs, antibiotics) * patients with severe xerostomia or with gougerot-sjögren's syndrome. * subjects undergoing treatment for cancer * pregnant or breastfeeding women * smokers of \> 10 cigarettes/day * impossibility to give information about the subject (subject in an emergency situation, difficulties in understanding the french language, etc.). * subject under safeguard of justice * subject under guardianship or curatorship
a study to assess the effect of ticagrelor in reducing the number of days with pain in patients with sickle cell disease

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease

this is a randomised, double-blind, double-dummy, parallel-group, placebo-controlled, study evaluating 2 doses of ticagrelor in 90 patients aged 18 to 30 years, with sickle cell disease (scd). patients will be randomised to double-blind double-dummy treatment period in a 1:1:1 ratio (30 to each treatment group) to receive ticagrelor 10 mg twice daily (bid), or ticagrelor 45 mg bid, or placebo bid to determine the frequency of days with pain using an electronic diary (ediary) every day. approximately 180 patients will be enrolled. patient will be followed for safety assessment during and after 2 weeks of treatment completion. during the 16 week treatment period, patients will complete a daily ediary concerning daily pain intensity, pain location, use of analgesics and absence from school or work. at the end of the study patients will be asked to rate the change in their sickle cell pain compared to the start of treatment. platelet aggregation will be measured and reported as p2y12 reaction units (pru) pre-dose and 2 hours post-dose at week 4 and week 5 after treatment start. pharmacokinetic (pk) parameters will be measured at 2 hours post-dose at week 4, and pre-dose and at 2 hours post-dose at week 5. biomarkers will be assessed pre-dose at week 4, week 5 and week 8. during the study, patients will be evaluated for adverse events (aes) including bleeding and vaso-occlusive crisis (voc).

Eligibility criteria:
inclusion criteria: * confirmed medical history or diagnosis of homozygous sickle cell (hbss) or sickle beta-zero-thalassaemia (hbs/β0) by hplc * if treated with hydroxyurea, the dose must have been stable for 3 months exclusion criteria: * history of transient ischaemic attack or clinically overt cerebrovascular accident * moderate or severe hepatic impairment * treatment with chronic red blood cell transfusion therapy * pre-dominate cause of pain is not sickle cell disease related * chronic treatment with anticoagulants or antiplatelet drugs.

Keywords: sickle cell disease young adults hestia2 ticagrelor